My Profile

Search abstracts

Lewis Sheiner


2019
Stockholm, Sweden



2018
Montreux, Switzerland

2017
Budapest, Hungary

2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
KÝbenhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 15 (2006) Abstr 886 [www.page-meeting.org/?abstract=886]


Poster: Applications- Anti-infectives


Nele Mueller-Plock A Population Pharmacokinetic Model for the Simultaneous Description of Linezolid Tissue and Plasma Disposition in Healthy Volunteers and Septic Patients

Plock, N.(1), C. Buerger(1), K. Kuester(1), C. Joukhadar(2), S. Kljucar(3), C. Kloft(1,4)

(1)Freie Universitaet Berlin, Institute of Pharmacy, Berlin, Germany; (2)University School of Medicine, Vienna, Austria; (3)DRK Kliniken Berlin Westend, Berlin, Germany; (4)Martin-Luther-Universitaet Halle-Wittenberg, Faculty of Pharmacy, Halle, Germany

PDF of poster

Objectives: Linezolid, the first member of the oxazolidinones, has been approved for the treatment of severe gram-positive infections. The aim of the study was to characterise the subcutaneous (sc) and muscular (im) tissue pharmacokinetics (PK) of unbound drug in healthy volunteers and septic patients applying the microdialysis and population analysis technique.

Methods: 34 individuals (24 patients) were treated with 600 mg linezolid bid as iv infusion with the exception of oral multiple dosing for healthy volunteers. Samples were taken after single dose and at steady state over a period of 8 hours. Unbound concentrations were determined in plasma and tissue placing two microdialysis probes in each subject (sc and im). Population pharmacokinetic analysis was carried out using the software NONMEM.

Results: Linezolid disposition in ultrafiltrate was best described by a two-compartment model including a nonlinear influence on clearance (CL) implemented by an additional inhibition compartment. CL was estimated to be 11.5 L/h with a 57% noninhibitable fraction (VAR). Central and peripheral distribution volumes were estimated to be 20 L (V2) and 27 L (V3), respectively. Interindividual varibility (IIV) was established for CL, V2, V3, KA and VAR ranging between 20% and 79% (ωKA). Creatinine clearance, thrombocytes and weight were included as covariates on CL and weight on V3, thus reducing unexplained parameter variability by 7-41%. Unbound sc and im tissue concentrations were incorporated into the model using two additional compartments, each parameterised with assumed equal monodirectional rates into and out of the compartment. Parameters previously obtained for ultrafiltrate were fixed. Tissue penetration was assessed by using partition coefficients PC23 and PC24 for sc and im tissue, respectively, which were estimated to be 1.05 for PC23 and 1.07 for PC24. Between occasion variability on PC23 and IIV on PC24 yielded values of 44% and 28%. Parameters were generally estimated with good precision (RSE<47%).

Conclusions: Unbound linezolid pharmacokinetics in tissue and plasma of both populations were successfully described by the population pharmacokinetic modelling approach. In general linezolid penetrated well into tissue fluid but displayed high variability. Inclusion of covariates significantly reduced unexplained variability, a prerequisite for predicting unbound tissue concentrations and individualisation of antimicrobial therapy.